Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125271 | 0.90 | TACR1 (1.00) | TACR1SGMS2 | |
| SCHEMBL6870073 | 0.85 | TACR1 (0.61) | TACR1SGMS2 | |
| SCHEMBL6637377 | 0.85 | TACR1 (0.83) | TACR1 | |
| Hydrochloric Acid SCHEMBL905337 | 0.84 | TACR1 (0.81) | TACR1 | |
| SCHEMBL6862358 | 0.83 | TACR1 (0.72) | TACR1 | |
| SCHEMBL17476477 | 0.80 | TACR1 (0.83) | TACR1 | |
| SCHEMBL5779622 | 0.76 | TACR1 (0.75) | TACR1 | |
| SCHEMBL6862193 | 0.76 | TACR1 (0.80) | TACR1 | |
| SCHEMBL4114128 | 0.76 | TACR1 (0.69) | TACR1SGMS2 | |
| Hydrochloric Acid SCHEMBL6869633 | 0.76 | TACR1 (0.78) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2016-02-04 | — | — | US | claimed |
| US-20090253698-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2009-10-08 | — | — | US | claimed |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2005-05-19 | — | — | US | claimed |
| EP-1171419-B1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | claimed |
| US-20020040060-A1 | Biphenyl derivatives | BOS MICHAEL (CA) | 2002-04-04 | — | — | US | claimed |
| EP-1171419-A1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-16 | — | — | EP | claimed |
| US-6291465-B1 | Biphenyl derivatives | HOFFMANN-LA ROCHE INC. | 2001-09-18 | — | — | US | claimed |
| WO-2000053572-A1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-14 | — | — | WO | claimed |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2019-02-12 | — | — | US | disclosed |
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2018-03-15 | — | — | US | disclosed |
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2016-02-04 | — | — | US | disclosed |
| US-9186404-B2 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2015-11-17 | — | — | US | disclosed |
| US-20090253698-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2009-10-08 | — | — | US | disclosed |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2005-05-19 | — | — | US | disclosed |
| EP-1171419-B1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | disclosed |
| US-6552088-B2 | 2'-methyl-biphenyl-2-carboxylic acid-(3,5-bis-trifluoromethyl-benzyl)-methyl-amide, for example; treating disease related to neurokinin 1 receptor | HOFFMANN-LA ROCHE INC. | 2003-04-22 | — | — | US | disclosed |
| US-20020040060-A1 | Biphenyl derivatives | BOS MICHAEL (CA) | 2002-04-04 | — | — | US | disclosed |
| EP-1171419-A1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-16 | — | — | EP | disclosed |
| US-6291465-B1 | Biphenyl derivatives | HOFFMANN-LA ROCHE INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000053572-A1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | TACR1, TACR2, NPSR1 | TACR1 1/4885SGMS2 1165/4885 |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | TACR1, TACR2, NMUR1 | TACR1 1/4885SGMS2 1116/4885 |
| US-20020040060-A1 | Biphenyl derivatives | NR1H4, NR1H2, NR1H3 | TACR1 16/4885SGMS2 3176/4885 |
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | TACR1, TACR2, NMUR1 | TACR1 1/4885SGMS2 1116/4885 |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | TACR1, TACR2, NPSR1 | TACR1 1/4885SGMS2 1165/4885 |
| US-20090253698-A1 | Brain, Spinal and Nerve Injury Treatment | TACR1, TACR2, NMUR1 | TACR1 1/4885SGMS2 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.